Lab Seeks Approval to Import Obscure Synthetic Drug Substance
Published Date: 4/3/2026
Notice
Summary
Lipomed/LGC Standards wants to become an official importer of certain controlled substances, like 3-Fluoro-N-methylcathinone. This means companies involved with these drugs can comment or ask for a hearing by May 4, 2026. If approved, it could impact how these substances enter the U.S., but no direct costs are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Import Registration Excludes Finished Dosage Forms
The notice says placement of these drug codes on the company's registration does not automatically approve later permits, and authorization will not extend to the import of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale. Permit approvals will only occur when activity is consistent with 21 U.S.C. 952(a)(2).
Importer Seeks to Supply Analytical Standards
On February 11, 2026, Lipomed/LGC Standards applied to be registered to import many Schedule I and II controlled substances (examples include 3-Fluoro-N-methylcathinone, cathinone, methcathinone, mephedrone, GHB, fentanyl-related compounds, LSD, psilocybin, and many others). The company says it plans to import analytical reference standards for distribution to its customers for research and analytics purposes.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in